company background image
3218

Universal Vision Biotechnology TPEX:3218 Stock Report

Last Price

NT$298.50

Market Cap

NT$23.9b

7D

-3.7%

1Y

2.1%

Updated

23 Sep, 2022

Data

Company Financials +
3218 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance5/6
Financial Health5/6
Dividends3/6

3218 Stock Overview

Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China.

Universal Vision Biotechnology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Universal Vision Biotechnology
Historical stock prices
Current Share PriceNT$298.50
52 Week HighNT$353.50
52 Week LowNT$210.00
Beta0.73
1 Month Change-11.21%
3 Month Change10.56%
1 Year Change2.09%
3 Year Change503.90%
5 Year Change1,073.88%
Change since IPO1,471.93%

Recent News & Updates

Shareholder Returns

3218TW HealthcareTW Market
7D-3.7%-2.3%-2.4%
1Y2.1%10.7%-15.9%

Return vs Industry: 3218 underperformed the TW Healthcare industry which returned 10.7% over the past year.

Return vs Market: 3218 exceeded the TW Market which returned -15.9% over the past year.

Price Volatility

Is 3218's price volatile compared to industry and market?
3218 volatility
3218 Average Weekly Movement6.0%
Healthcare Industry Average Movement4.6%
Market Average Movement5.0%
10% most volatile stocks in TW Market8.2%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 3218 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 3218's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992n/aKenneth Luhttps://www.eyecenter.com.tw

Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. Its clinics provide laser vision correction surgery for myopia, hyperopia, astigmatism, and presbyopia; intraocular lens surgery for presbyopia and cataract; phacoemulsification and femtosecond laser for cataract surgery; and myopia control services, as well as services for dry eyes, retinal detachment, macular degeneration, strabismus, amblyopia, and other eye diseases. The company also offers vision products and services, including a range of eyeglass frames, multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, regular/colored contact lenses, eye supplements, etc.; eye plastic and micro cosmetic surgery; and customized aesthetic medicine consulting.

Universal Vision Biotechnology Fundamentals Summary

How do Universal Vision Biotechnology's earnings and revenue compare to its market cap?
3218 fundamental statistics
Market CapNT$23.86b
Earnings (TTM)NT$718.88m
Revenue (TTM)NT$3.03b

33.2x

P/E Ratio

7.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
3218 income statement (TTM)
RevenueNT$3.03b
Cost of RevenueNT$1.16b
Gross ProfitNT$1.87b
Other ExpensesNT$1.15b
EarningsNT$718.88m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)8.99
Gross Margin61.58%
Net Profit Margin23.71%
Debt/Equity Ratio6.1%

How did 3218 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

53%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 3218 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3218?

Other financial metrics that can be useful for relative valuation.

3218 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.9x
Enterprise Value/EBITDA21.7x
PEG Ratio1.1x

Price to Earnings Ratio vs Peers

How does 3218's PE Ratio compare to its peers?

3218 PE Ratio vs Peers
The above table shows the PE ratio for 3218 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average61.2x
8403 ShareHope Medicine
11.9xn/aNT$4.3b
6879 TCI GENE
27.6xn/aNT$3.6b
1784 BIONET
134.4xn/aNT$2.0b
4139 Ma Kuang Healthcare Holding
70.9xn/aNT$2.3b
3218 Universal Vision Biotechnology
33.2x31.2%NT$23.9b

Price-To-Earnings vs Peers: 3218 is good value based on its Price-To-Earnings Ratio (33.2x) compared to the peer average (61.2x).


Price to Earnings Ratio vs Industry

How does 3218's PE Ratio compare vs other companies in the Asian Healthcare Industry?

Price-To-Earnings vs Industry: 3218 is expensive based on its Price-To-Earnings Ratio (33.2x) compared to the Asian Healthcare industry average (17.4x)


Price to Earnings Ratio vs Fair Ratio

What is 3218's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3218 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.2x
Fair PE Ratio31.9x

Price-To-Earnings vs Fair Ratio: 3218 is expensive based on its Price-To-Earnings Ratio (33.2x) compared to the estimated Fair Price-To-Earnings Ratio (31.9x).


Share Price vs Fair Value

What is the Fair Price of 3218 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3218 (NT$298.5) is trading below our estimate of fair value (NT$843.74)

Significantly Below Fair Value: 3218 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Universal Vision Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


31.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3218's forecast earnings growth (31.2% per year) is above the savings rate (0.7%).

Earnings vs Market: 3218's earnings (31.2% per year) are forecast to grow faster than the TW market (7% per year).

High Growth Earnings: 3218's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 3218's revenue (21% per year) is forecast to grow faster than the TW market (7.9% per year).

High Growth Revenue: 3218's revenue (21% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 3218's Return on Equity is forecast to be high in 3 years time (35.9%)


Discover growth companies

Past Performance

How has Universal Vision Biotechnology performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


38.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 3218 has high quality earnings.

Growing Profit Margin: 3218's current net profit margins (23.7%) are higher than last year (23.2%).


Past Earnings Growth Analysis

Earnings Trend: 3218's earnings have grown significantly by 38.3% per year over the past 5 years.

Accelerating Growth: 3218's earnings growth over the past year (29.3%) is below its 5-year average (38.3% per year).

Earnings vs Industry: 3218 earnings growth over the past year (29.3%) exceeded the Healthcare industry 14.6%.


Return on Equity

High ROE: 3218's Return on Equity (30.9%) is considered high.


Discover strong past performing companies

Financial Health

How is Universal Vision Biotechnology's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 3218's short term assets (NT$1.8B) exceed its short term liabilities (NT$906.1M).

Long Term Liabilities: 3218's short term assets (NT$1.8B) exceed its long term liabilities (NT$745.5M).


Debt to Equity History and Analysis

Debt Level: 3218 has more cash than its total debt.

Reducing Debt: 3218's debt to equity ratio has increased from 0.2% to 6.1% over the past 5 years.

Debt Coverage: 3218's debt is well covered by operating cash flow (895.7%).

Interest Coverage: 3218's interest payments on its debt are well covered by EBIT (98.7x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Universal Vision Biotechnology current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


1.60%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 3218's dividend (1.6%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.45%).

High Dividend: 3218's dividend (1.6%) is low compared to the top 25% of dividend payers in the TW market (6.68%).


Stability and Growth of Payments

Stable Dividend: 3218's dividend payments have been volatile in the past 10 years.

Growing Dividend: 3218's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (52.9%), 3218's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (46.2%), 3218's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

11.3yrs

Average management tenure


CEO

Kenneth Lu

12.58yrs

Tenure

Mr. Kenneth Lu is President of Universal Vision Biotechnology Co., Ltd. since February 1, 2010. Mr. Lu has M.B.A. from National Taiwan University.


Leadership Team

Experienced Management: 3218's management team is seasoned and experienced (11.3 years average tenure).


Board Members

Experienced Board: 3218's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 22.16% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
3.88%
Schroder Investment Management (Hong Kong) Limited
3,099,600NT$925.2m0%0.16%
2.55%
abrdn plc
2,037,000NT$608.0m17.93%0.02%
2.42%
The Vanguard Group, Inc.
1,937,250NT$578.3m0.05%no data
2.25%
AllianceBernstein L.P.
1,796,550NT$536.3m0%0.01%
1.9%
CI Global Asset Management
1,518,064NT$453.1m0%0.03%
1.69%
Columbia Management Investment Advisers, LLC
1,351,350NT$403.4m0%no data
1.08%
Allianz Asset Management AG
862,050NT$257.3m-56.11%0.01%
1.07%
WCM Investment Management, LLC
856,800NT$255.8m-33.77%0.02%
1.05%
Matthews International Capital Management, LLC
836,850NT$249.8m0%0.05%
0.73%
BlackRock, Inc.
581,600NT$173.6m-0.2%no data
0.53%
Dimensional Fund Advisors LP
427,427NT$127.6m1.64%no data
0.53%
Capital Investment Trust Corporation
424,083NT$126.6m44.39%0.29%
0.42%
Value Partners Hong Kong Limited
332,850NT$99.4m0%0.07%
0.4%
Causeway Capital Management LLC
319,200NT$95.3m-4.1%0.02%
0.32%
Union Asset Management Holding AG
259,350NT$77.4m0%no data
0.32%
Eastspring Investments (Singapore) Limited
256,714NT$76.6m0%0.01%
0.32%
UBS Asset Management
256,200NT$76.5m-64.53%no data
0.25%
Schroder Investment Management Limited
197,400NT$58.9m0%no data
0.11%
Nikko Asset Management Co., Ltd.
88,200NT$26.3m0%no data
0.076%
Yuanta Securities Investment Trust Co., Ltd.
60,421NT$18.0m-91.32%no data
0.075%
KGI Securities Investment Trust Co. Ltd.
59,849NT$17.9m217.6%0.18%
0.059%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
47,250NT$14.1m18.42%no data
0.058%
State Street Global Advisors, Inc.
46,271NT$13.8m0%no data
0.056%
Epoch Investment Partners, Inc.
44,738NT$13.4m0%0.01%
0.022%
American Century Investment Management Inc
17,850NT$5.3m0%no data

Company Information

Universal Vision Biotechnology Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Universal Vision Biotechnology Co., Ltd.
  • Ticker: 3218
  • Exchange: TPEX
  • Founded: 1992
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: NT$23.859b
  • Shares outstanding: 79.93m
  • Website: https://www.eyecenter.com.tw

Number of Employees


Location

  • Universal Vision Biotechnology Co., Ltd.
  • No.3-1 Yuanqu Street
  • 4th Floor
  • Taipei
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
3218TPEX (Taipei Exchange)YesCommon StockTWTWDJan 2004

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/23 00:00
End of Day Share Price2022/09/22 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.